October 14, 2019
TOLREMO selected to join highly competitive BaseLaunch Accelerator
We are very proud of having joined BaseLaunch, a pharma-backed accelerator that supports young companies dedicated to developing transformative technologies to change patient outcomes.
We thank the selection committee of experienced healthcare experts for backing our application and the entire BaseLaunch team for their support!
September 10, 2019
#TOP100SSU: TOLREMO is One of Switzerland's Most Promising Startups
TOLREMO therapeutics jumped from the amazing 31st place in 2018 to the outstanding 16th place in the overall ranking of this year’s Top100 Swiss Startup Award. Top10 seems to be only a very short distance ahead. Moreover, TOLREMO defended its place among the Top5 biotech startups in the country. A big ‘THANK YOU’ to the whole TOLREMO team that is working very hard to scale up development each year and to our investors that make this incredible journey possible – you are the best!
-> Check www.top100startups.swiss for more details
August 9, 2019
TOLREMO on CNN Money Switzerland
Our CEO Stefanie Flückiger-Mangual met with TV anchor Hannah Wise from CNN Money Switzerland to talk about the Swiss start-up ecosystem and how TOLREMO aims to turbo-charge existing cancer therapies to extend patient benefit.
June 7, 2019
TOLREMO is a 2019 »venture» finalist
TOLREMO therapeutics is one of the top 10 finalists in the “Health & Nutrition” vertical of this year’s »venture» business plan competition. »venture» is Switzerland’s leading startup contest for entrepreneurs with innovative business ideas – with workshops, coaching and networking opportunities »venture» provides the essential environment to turn the participant’s ideas into reality.
May 3, 2019
TOLREMO on stage at the Swiss Biotech Day 2019 (7.5.2019 at Congress Center in Basel)
Great news on the TOLREMO front: We are thrilled to be part of this year’s Swiss Biotech Day. Our CEO Stefanie Flückiger-Mangual gets the chance to present TOLREMO at this vivid annual get-together of the Swiss biopharmaceutical industry. Be kindly invited to join our afternoon talk in Room Montreal starting at 1.30pm.
Visit the Biotech Day 2019 webpage to get more information and impressions about this high-caliber event.
April 4, 2019
TOLREMO is one of the Bilan ‘Top 50 Startups in Which to Invest 2019’
The business magazine Bilan nominated TOLREMO therapeutics as one of the top 50 Swiss startups in which to invest in 2019. In a ceremonious event that took place at the Hotel Savoy in Lausanne, TOLREMO was selected as one of 4 companies in the Biotech category.
March 28, 2019
BioPharma Dealmakers - TOLREMO featured in March 2019 edition
Eradicating the seed of drug resistance - TOLREMO therapeutics AG aims to fundamentally change the way modern cancer drugs are used. The company’s resistance-breaking add-on therapies boost the long-term efficacy of existing cancer drugs by inhibiting nongenetic mechanisms of cancer drug resistance.
March 11, 2019
Labiotech.eu Interview – How to Make Cancer Drug Resistance Futile
For many solid tumors, treatments undergo a cycle: the drugs initially work well, the tumor shrinks, but then becomes resistant again. Stefanie Flückiger-Mangual, CEO of the Swiss biotech TOLREMO, believes that this cycle can be stopped.
February 21, 2019
Stefanie Flückiger-Mangual in Swiss Venture Capital Report 2019
The Swiss Venture Capital Report is the reference publication for investments in Swiss start-ups. TOLREMO’s rapid value generation and highly successful fundraising rounds make the company stand out in the ecosystem. In the ‘faces behind the figures’ section, our CEO Stefanie Flückiger-Mangual talks about TOLREMO and it’s rapid progression.
Take a look at the Swiss Venture Capital Report 2019:
-> Download article (Flückiger-Mangual on page 27)
December 20, 2018
Biotech Showcase 2019 (Hilton San Francisco Union Square)
We are delighted to announce that TOLREMO has been chosen to present at Biotech showcase 2019 in San Francisco. Our foreseen presentation time slot is as follows:
Date: Wednesday, January 9, 2019
Time: 8:30 AM
Track: Franciscan D (Ballroom Level)
We cordially invite you to join our session and look forward to meeting you there!
October 31, 2018
Meet us @ Bio Europe 2018 in Copenhagen
The 24th Annual International Partnering Conference takes place from November 5th to 7th in beautiful Copenhagen. TOLREMO therapeutics will be present to meet with industry partners, expand business contacts and to gain insight into latest industry trends – feel free to get in touch (email@example.com). See you soon at the Bella Center in Copenhagen!
September 5, 2018
TOLREMO is one of the TOP 5 most promising Swiss Biotech Startups in 2018
TOLREMO therapeutics has made it directly into this year’s Top 5 Biotech Startups in Switzerland! Ranked 31st in the nation-wide rating, TOLREMO proudly takes its place as of the best 100 Swiss start-ups in the prosperous Swiss Startup ecosystem. Many thanks to all investors and experts who believe in our potential and made this outstanding achievement possible! To the article
August 30, 2018
Female Founders – Von der Idee zum Erfolg
Dr. Stefanie Flückiger-Mangual, CEO & Co-founder of TOLREMO therapeutics, was invited to share her industry insights and experiences as female founder of a rapidly growing biotechnology company. Together with other entrepreneurs, the panel discussed the growing role of women in a predominantly men-dominated business and investor environment. The event was covered by the Swiss Startup News channel startupticker.ch.
-> To the startupticker.ch article
-> Download review pdf
May 17, 2018
BioCentury – TOLREMO one of Europe’s top academic spinouts
By Lauren Martz
TOLREMO therapeutics was covered by BioCentury Innovations. In ‘Europe’s Piece of the Pie’ TOLREMO was named one of Europe’s top academic spinouts with disclosed financing.
-> Read the full article here (pdf)
September 28, 2017
BioWorld – TOLREMO aims to choke cancer drug resistance at birth
By Cormac Sheridan
DUBLIN – For too many cancer patients, therapy still means no more than prolonging the inevitable. Cancer drug developers are proud to trot out numbers detailing objective response rates to novel drug candidates, along with progression-free survival and overall survival data. They're not shy about charging high prices for their product offerings either. But the grim reality is that five-year survival rates for many cancers – including lung, liver and esophageal – are still well below 50 percent, even if cancer death rates continue to decline in the U.S. and other high-income countries.
-> Read the article